

# GRANTS

*October 2017*

# Awards & Acknowledgments

TiGenix and Coretherapix has been recognized as an innovative SME by the Ministry of Economy and Competitiveness.

This seal, created for small and medium-sized enterprises (SMEs), officially recognizes the effort of our company to research and innovate in the medical sector.

## TiGenix



**INNOVATE SME**

Valid until Oct 25th 2019



## Coretherapix



**INNOVATE SME**

Valid until Oct 26th 2019



## Development of the clinical trial of Cx611 for severe SEPSIS.

- TIGENIX has been the beneficiary of the “Emplea” Grant in the 2016 call, financed through the State Program for Promotion of Talent and its Employability, included in the State Plan for Scientific, Technical and Innovation Research 2013-2016, and by the Ministry of Economy and Competitiveness, for the recruitment of university graduates for the development of the clinical trial of Cx611 for severe SEPSIS.
- Reference: EMP-TU-2016-5196
- Duration: 2017-2020



## Cardiac progenitor cell therapy for treatment of ventricular tachycardia(CPCs-TV)

- Consortium formed by the Hospital Gregorio Marañón and TiGenix (leader of the consortium), the project focuses on the development of preclinical tests necessary to obtain the IMPD of the product AlloCSC-01, and a phase I / IIa clinical trial to verify the safety and efficacy of the product in the treatment of ventricular tachycardia.
- This project was co-financed by the Ministry of Economy and Competitiveness, within the framework of the Challenge-Collaboration Program of the State Program for Research, Development and Innovation in the Society's Challenges, within the framework of the State Plan for Scientific, Technical and Innovation Research 2013- 2016 and by the European Regional Development Fund (ERDF).
- Reference: RTC-2015-4398-1
- Duration: 2015-2017.





## Development and validation of new drug characterization procedures based on advanced therapies.

- TIGENIX has been the beneficiary of the “Torres Quevedo” Grant in the 2014 call, financed through the State Program for Promotion of Talent and its Employability, included in the State Plan for Scientific, Technical and Innovation Research 2013-2016, and by the Ministry of Economy and Competitiveness, for the recruitment of PhD.
- Reference: PTQ-14-06815
- Duration: 2016-2018



Unión Europea  
Fondo Social Europeo  
"El FSE invierte en tu futuro"



## SEPCELL: Restoring the immune system homeostasis and organ function in severe community acquired pneumonia- induced sepsis through adipose derived allogeneic stem cells

- Led by TiGenix, the consortium intends to test in the clinical setting (phase Ib/IIa clinical trial) the safety and feasibility of eASC treatment in patients developing severe sepsis due to community-acquired pneumonia.
- This project was funded by the European Union under the programme H2020.
- <http://www.sepcell.eu/>
- Reference: H2020 681031
- Duration: 2015-2018

SEPCELL



# Finished Funding projects



- **REGENER-AR:** Bringing Regenerative Medicine into the market: Allogeneic eASCs Phase IB/IIA clinical trial for treating Rheumatoid Arthritis. Reference: FP7 279174. [http://cordis.europa.eu/project/rcn/102108\\_en.html](http://cordis.europa.eu/project/rcn/102108_en.html)
- **CARE-MI:** Cardio repair european multidisciplinary initiative. Reference: FP7 242038. [http://cordis.europa.eu/project/rcn/94265\\_en.html](http://cordis.europa.eu/project/rcn/94265_en.html)
- **CardioNet:** Translational Training network on the Cellular and Molecular Bases of Heart Homeostasis and Repair. Reference: FP7 289600.



- **PROCARDIO:** Development of advanced production technologies and validation of an Allogeneic cellular product for the treatment of cardiovascular disease. Reference: IPT-2011-1307-010000.
- **ASCIVAR-ASCS:** Allogeneic for the intravenous treatment of inflammatory diseases: rheumatoid arthritis. Reference: IPT-010000-2010-040.
- **Converting stem cells into drugs:** allogeneic ASCs and bioengineering in clinical applications. Reference: PSE-010000-2009-3
- **Design and implementation of Europe's largest capacity cell therapy plant.** Reference: PCT-010000-2009-24



- **ONCOLÓGICA:** New strategies based on biomarkers for cancer detection, prognosis, prediction of response and development of new treatments. Reference: CEN-20091016.



- **Cx601:** Clinical development Phase III for the first drug in Europe based on allogeneic stem cells derived from adipose tissue. Turning Cell Therapy into Reality.
- **Allogeneic stem cell potential as a new therapeutic approach in autoimmune inflammatory diseases:** Application in severe pathologies with high therapeutic need and validation by clinical trial.